PT  - JOURNAL ARTICLE
AU  - Nomura, Akihiro
AU  - Ikeda, Takaaki
AU  - Fujimoto, Toshiki
AU  - Morita, Yusaku
AU  - Taniguchi, Chie
AU  - Ishizawa, Tetsuro
AU  - Tabuchi, Takahiro
TI  - Heated tobacco products and a telemedicine smoking cessation programme: A retrospective study
AID  - 10.1101/2022.02.15.22270564
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.15.22270564
4099  - http://medrxiv.org/content/early/2022/02/16/2022.02.15.22270564.short
4100  - http://medrxiv.org/content/early/2022/02/16/2022.02.15.22270564.full
AB  - Objectives Japan is one of the largest markets for heated tobacco products (HTP), and the number of HTP users, including dual users, is burgeoning. However, it is not yet clear whether a telemedicine smoking cessation programme is helpful for nicotine-dependent people who use HTPs.Methods We retrospectively evaluated the effectiveness of a telemedicine smoking cessation programme for nicotine-dependent tobacco product users, comparing short- and long-term continuous abstinence rates (CAR) from 9 to 24 weeks (CAR9-24) and 9 to 52 weeks (CAR9-52). We divided programme participants into 1) exclusively cigarette users, 2) exclusively HTP users, and 3) dual users. Using logistic regression with inverse probability weighting, an adjusted odds ratio (aOR) with a 95% confidence interval (CI) for CAR was calculated to compare the differences among the three groups.Results We analysed 733 telemedicine smoking cessation programme participants (exclusively cigarette users, 52%; exclusively HTP users, 31%; and dual-users, 16%) dating August 2018 to October 2020. HTP users had higher CARs than the exclusively cigarettes group in CAR9-24 (aOR, 1.12; CI, 1.02–1.23; p=0.02) and CAR9-52 (aOR 1.09; CI, 0.99–1.19; p=0.08). Conversely, dual users had lower CARs than the exclusively cigarettes group in the CAR9-24 (aOR, 0.85; CI, 0.76–0.95; p=0.004) and CAR9-52 (aOR, 0.88; CI, 0.79–0.97; p=0.01).Conclusions Exclusively HTP users achieved higher CARs, whereas dual users had lower CARs than exclusively cigarette users over short- and long-term periods. A telemedicine smoking cessation programme may be a reasonable option for exclusively HTP users.What is already known on this topic Telemedicine smoking cessation programmes can be helpful for some nicotine-dependent people.What this study adds Exclusively HTP users had higher continuous abstinence rates (CARs) than the exclusively cigarettes group. Conversely, dual users had lower CARs than the exclusively cigarettes group. A telemedicine smoking cessation programme may be a reasonable option for exclusive HTP users.How this study might affect research, practice, or policy In addition to conventional combustible cigarettes, the number of HTP users, including dual users, is burgeoning in Japan. This study could add an effective and alternative option for HTP users to remotely quit smoking in the era of COVID-19 and beyond.Competing Interest StatementA. Nomura received consulting fees from CureApp, Inc. and is the co-founder of CureApp Institute. T. Ishizawa is the chief medical officer and a shareholder of Linkage, Inc. T. Tabuchi received consulting fees from Linkage, Inc. Other authors have no conflicts of interest to disclose.Funding StatementThis study was supported by a KAKEN Grant-in-Aid for Scientific Research (A) (21H04856).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Kanazawa University institutional review board (2020-206 [3573]).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the study findings are available from the corresponding author upon reasonable request.